SSY Pharmaceutical Research Institute SSY Pharmaceutical Research Institute

Corporate email

中文/EN

简体中文

English

Shi Si Pharmaceutical Research Institute
scroll down

Drug Research Institute of SSY Group Limited

（Hebei Guangxiang Technology Co., Ltd.）

Affiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development. The company is dedicated to providing comprehensive and professional research and consulting services for excellent enterprises at home and abroad. Its main business covers pharmaceutical research, drug registration, clinical research, clinical trials, medical market, clinical trial quotation, project evaluation, patent affairs, information management and industrialization, and so on.

88 new products were approved
88

88 new products were approved

66 varieties passed the consistency evaluation
66

66 varieties passed the consistency evaluation

432 patents have been declared
432

432 patents have been declared

276 patents have been authorized
276

276 patents have been authorized

View More +

Technology platform

Innovation, Openness, Inclusiveness, and Sharing

It has created a world-class R&D and innovation platform

National Enterprise Technology Center recognized by five Ministries including the National Development &Reform Commission

Post-Doctoral Research Center

Major National Science and Technology Projects Research Institute

National and Local Joint Engineering Laboratory

Hebei Technology Innovation Center for Large-Volume Injection

Hebei Chemical Aseptic Preparation Industrial Technology Research Center

Technology platform
Homepage video call
Close Video

Lead The Future By Innovation

Continuously strengthen the innovation-driven development, Vigorously promote the integration of production and research. Strengthen and optimize the five domains: New drugs, Biological drugs, Traditional Chinese medicine, Generic drugs and APIs.

View More +

ORGANIZATION

News Center

Group Announcement Media coverage Group News
Shijiazhuang Sihua Pharmaceutical Group’s two specifications of pitavastatin calcium tablets have been approved.

2023-07-05

Shijiazhuang Sihua Pharmaceutical Group’s two specifications of pitavastatin calcium tablets have been approved.

On July 4, Shijiazhuang No.4 Pharmaceutical Group obtained drug production registration approvals from the National Medical Products Administration for two specifications—1mg and 2mg—of Pivastatin Calcium Tablets, Class 4 chemical drugs, which are deemed to have passed the consistency evaluation. As of now, the Group has 52 varieties comprising 69 specifications that have either passed or been deemed to have passed the national generic drug quality and efficacy consistency evaluation.
Shijiazhuang Fourth Pharmaceutical Group Selected for China’s Most Influential List in the Pharmaceutical Industry

2023-07-05

Shijiazhuang Fourth Pharmaceutical Group Selected for China’s Most Influential List in the Pharmaceutical Industry

On July 3, the 15th China Pharmaceutical Industry Development Summit Forum, hosted by the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce, was held in Harbin. During the conference, the “2022–2023 List of China’s Most Influential Companies in the Pharmaceutical Industry” was released. Shijiazhuang Sihua Pharmaceutical Group was honored with two prestigious awards: being named among the Top 100 Chinese Pharmaceutical Manufacturers and recognized as a Pioneer Enterprise in China’s Independent Pharmaceutical Innovation.
Shijiazhuang Sihua Pharmaceutical Group’s Tirofiban Hydrochloride Injection Concentrate (15 ml) Has Been Approved.

2023-06-30

Shijiazhuang Sihua Pharmaceutical Group’s Tirofiban Hydrochloride Injection Concentrate (15 ml) Has Been Approved.

On June 29, the concentrated solution for intravenous injection of tirofiban hydrochloride (15 ml), submitted by Shijiazhuang Fourth Pharmaceutical Group, received drug production registration approval from the National Medical Products Administration and is deemed to have passed the evaluation of consistency in quality and efficacy for generic drugs. This is the group’s 34th new product approved so far this year.
Shijiazhuang Fourth Pharmaceutical Group has been listed on the "Top 100 Chinese Chemical Pharmaceutical Companies" list.

2023-06-28

Shijiazhuang Fourth Pharmaceutical Group has been listed on the "Top 100 Chinese Chemical Pharmaceutical Companies" list.

On the evening of June 27, the 2022 Mishi Conference (China Pharmaceutical and Health Industry Symbiosis Conference), hosted by Minenet, opened in Huzhou, Zhejiang Province. During the conference, the highly anticipated 2022 Top 100 Chinese Pharmaceutical Industry Rankings were released. Shijiazhuang Fourth Pharmaceutical Group was named among the “Top 100 Chinese Chemical Pharmaceutical Enterprises of 2022” thanks to its strong R&D capabilities and market influence, ranking 39th on the list.
View more+
The Digital Journey of a Bag of Intravenous Fluids

The Digital Journey of a Bag of Intravenous Fluids

2023-05-12

Shijiazhuang Sihua Pharmaceutical Group is a leading enterprise in China’s large-volume parenteral solutions industry. In recent years, Shijiazhuang Sihua has comprehensively upgraded its production equipment for large-volume parenteral solutions and adopted digital technologies, significantly enhancing the company’s core competitiveness. Last December, the company’s proposed project on digital R&D and design of pharmaceutical products was included in the 2022 List of Outstanding Smart Manufacturing Scenarios released by four government departments, including the Ministry of Industry and Information Technology and the National Development and Reform Commission.
A New Era, a New Journey, and Great New Achievements | Shijiazhuang Sihua Pharmaceutical Group Integrates Industry, Academia, and Research, Receiving Approval for New Products Every Month

A New Era, a New Journey, and Great New Achievements | Shijiazhuang Sihua Pharmaceutical Group Integrates Industry, Academia, and Research, Receiving Approval for New Products Every Month

2022-12-22

On December 5, in the liquid-phase laboratory of the Pharmaceutical Research Institute of Shijiazhuang Sihua Pharmaceutical Group, Yang Xian, head of the group’s Innovation Department, stared intently at the instrument screen, carefully recording the purity data for ADN-9, an innovative drug for combating liver fibrosis. Team members were busily working—some handling small and large test tubes and various instruments—each person engaged in a tense yet orderly manner.
Tian Pengmei, CEO of Shijiazhuang Fourth Pharmaceutical Group and General Manager of the Strategic Development and Human Resources Center: Building a bigger stage for talents to showcase their abilities.

Tian Pengmei, CEO of Shijiazhuang Fourth Pharmaceutical Group and General Manager of the Strategic Development and Human Resources Center: Building a bigger stage for talents to showcase their abilities.

2022-11-21

“High-end talent can both come in and stay—key to this is providing them with a platform where they can fully demonstrate their abilities,” said Tian Pengmei, Executive President of Shijiazhuang Fourth Pharmaceutical Group and General Manager of the Strategic Development and Human Resources Center. She noted that the 20th National Congress of the Communist Party of China has charted the course for enterprises to further enhance their talent-development efforts. In the future, the group will adopt even more robust measures to create an even bigger stage for talented individuals to showcase their skills and potential.
View more+
The theoretical study group of the Party Committee of China Pharmaceutical University conducted a research visit to Shijiazhuang Fourth Pharmaceutical Group.

The theoretical study group of the Party Committee of China Pharmaceutical University conducted a research visit to Shijiazhuang Fourth Pharmaceutical Group.

Shijiazhuang Sihua Pharmaceutical Group Makes a Spectacular Appearance at the 21st China International Pharmaceutical Ingredients Exhibition.

Shijiazhuang Sihua Pharmaceutical Group Makes a Spectacular Appearance at the 21st China International Pharmaceutical Ingredients Exhibition.

On June 19, the 21st China Pharmaceutical Ingredients Exhibition (CPHI China 2023) and the 16th China Pharmaceutical Machinery, Packaging Equipment & Materials Exhibition (PMEC China 2023) kicked off with great fanfare at the Shanghai New International Expo Center (Pudong). The API Division of Shijiazhuang Sihua Pharmaceutical Group and the group’s Boshi Medical Devices’ domestic and international sales teams made a stunning debut with their new products.

2023-06-23

Safety First, Hardcore Competition—The Shijiazhuang Sihua Pharmaceutical Group’s Safety Production Knowledge Contest Kicks Off with Great Enthusiasm.

Safety First, Hardcore Competition—The Shijiazhuang Sihua Pharmaceutical Group’s Safety Production Knowledge Contest Kicks Off with Great Enthusiasm.

To further enhance the safety awareness of all employees and promote the safe, stable, and healthy development of the company, Shijiazhuang Sihua Pharmaceutical Group held a knowledge competition for “Safety Production Month” on June 14. After passing the preliminary written test, nine teams—each consisting of 27 employees who had been selected—stepped onto the stage with high spirits, ready to compete fiercely for the ultimate victory.

2023-06-15

View more+

To promote the cause of human health with strength from China

Join us+